



**Publikationer som använde sig av Svenska MS-registerdata  
(januari 2003- september 2008)**

**2008**

Thangarajh M, Gomez-Rial J, Hedström AK, Hillert J, Alvarez-Cermeño JC, Masterman T, Villar LM. Lipid-specific immunoglobulin M in CSF predicts adverse long-term outcome in multiple sclerosis. *Multiple Sclerosis* Aug 28. [Epub ahead of print].

Kobelt G, Berg J, Lindgren P, Jonsson B, Stawiarz L, Hillert J. Modeling the Cost-Effectiveness of a New Treatment for MS compared to Current Standard Practice in Sweden (An indirect comparison of a clinical trial with natalizumab with data from the Swedish MS Registry). *Multiple Sclerosis*, 2008 Jun;14(5):679-9

Martola J, Stawiarz L, Fredrikson S, Hillert J, Bergström J, Flodmark O, Aspelin P, Kristoffersen Wiberg M. Rate of ventricular enlargement in multiple sclerosis: a nine-year multiple resonance imaging follow-up study. *Acta Radiologica*, 2008 Jun;49(5):570-9

Rikard Carlsson, apoteksstuderande, examensarbete: Evaluation of the first year of natalizumab treatment of MS: a retrospective study at the MS Center, Sahlgrenska University Hospital, Gothenburg. *Master Thesis in Pharmacy 2008, handledare Jan Lycke*

Kristina Yilmaz, apoteksstuderande, examensarbete: Multiple sclerosis treatment with mitoxantrone: A retrospective study of patient selection, efficacy, and safety at the Department of Neurology, Sahlgrenska University Hospital. *Master Thesis in Pharmacy 2008, handledare Jan Lycke*

Jenny Silversparre, apoteksstuderande, examensarbete: Treatment of multiple sclerosis with interferon beta: a retrospective study of the risk to develop neutralizing antibodies. *Master Thesis in Pharmacy 2008, handledare Jan Lycke*

**2007**

Tedeholm H, Skoog B, Hillert J, Runmarker B, Stawiarz L, Andersen O. Att optimera historiska kontroller. Utvärdering av långtidseffekter av MS-behandling med "virtual placebo". En studie av MS naturalförlopp. *Läkartidningen*. 2007 May 30-Jun 3;104(22):1684-8

Smestad C, Brynedal B, Jonasdottir G, Lorentzen AR, Masterman T, Akesson E, Spurkland A, Lie BA, Palmgren J, Celius EG, Hillert J, Harbo HF. The impact of HLA-A and -DRB1 on age at onset, disease course and severity in Scandinavian multiple sclerosis patients. *Eur J Neurol*. 2007 Aug;14(8):835-40.

Lundmark F, Salter H, Hillert J. An association study of two functional promotor polymorphisms in the myeloperoxidase (MPO) gene in multiple sclerosis. *Mult Scler*. 2007 Jul;13(6):697-700



Nilsagård Y, Fedeli C, Gunnarsson L-G, Denison E. Clinical relevance using timed walk tests and 'timed up and go' testing in persons with Multiple Sclerosis. Reproducibility, correlations, and smallest percentage to detect genuine change. *Physiotherapy Research International* 2007;12(2): 105-114.

Martola J, Stawiarz L, Fredrikson S, Hillert J, Bergström J, Flodmark O, Kristoffersen-Wiberg M. Progression of non-age related callosal brain atrophy in multiple sclerosis. A nine years longitudinal MRI study representing four decades of disease development. *J Neurol Neurosurg Psychiatry*. 2007 Apr; 78(4):375-80.

Nilsagård Y, Gunnarsson L-G, Deinsion E. Self-perceived limitations of gait in persons with Multiple Sclerosis. *Advances in Physiotherapy* 2007; 9(3):136-143.

#### **2006**

Imrell K, Landtblom AM, Hillert J, Masterman T. Multiple sclerosis with and without CSF bands: Clinically indistinguishable but immunogenetically distinct. *Neurology* (2006) 67:1062-4.

Holmqvist P, Wallberg M, Hammar M, Landtblom AM, Brynhildsen J. Symptoms of multiple sclerosis in women in relation to sex steroid exposure. *Maturitas*. 2006 May 20;54(2):149-53.

Nilsagård Y, Denison E, Gunnarsson L-G. Evaluation of a single session with cooling garment for persons with multiple sclerosis - a randomized trial. *Disability and Rehabilitation* 2006;1(4):225-233.

#### **2005**

Flensner G., Ek A-C., Söderhamn O. Reliability and validity of the Swedish version of the Fatigue Impact scale (FIS). *Scandinavian Journal of Occupational Therapy*, 2005, 12: 170-180.

Flensner G. Fatigue in individuals with Multiple Sclerosis. Lived experiences and perceived impact in daily life. *Linköping University, Medical Dissertation No 917, Department of Medicine and Care, Division of Nursing Science, Faculty of Health Sciences, Linköping University, 2005.*

#### **2004**

Landtblom AM, Flensner G, Callander M, Stawiarz L. The Swedish MS registry points out an important clinical problem: physical and psychological fatigue is a main symptom in multiple sclerosis. *Läkartidningen*. 2004 Oct 28; 101(44):3456-7.

Inger Boström, sjuksköterska, Kristinehamn, "Är Värmland ett högriskområde för multipel skleros?". *Magisterarbete som lagts fram 20 Sept. 2004, Nordiska Vårdhögskolan, Göteborg.Handledare AM Landtblom, Max Petzold.*

Khademi M, Illes Z, Gielen AW, Marta M, Takazawa N, Baecher-Allan C, Brundin L, Hannerz J, Martin C, Harris RA, Hafler DA, Kuchroo VK, Olsson T, Piehl F, Wallstrom E.



T Cell Ig- and mucin-domain-containing molecule-3 (TIM-3) and TIM-1 molecules are differentially expressed on human Th1 and Th2 cells and in cerebrospinal fluid-derived mononuclear cells in multiple sclerosis. *J Immunol.* 2004 Jun 1;172(11):7169-76.

Guggenmos J, Schubart AS, Ogg S, Andersson M, Olsson T, Mather IH, Linington C. Antibody cross-reactivity between myelin oligodendrocyte glycoprotein and the milk protein butyrophilin in multiple sclerosis. *J Immunol.* 2004 Jan 1;172(1):661-8.

### 2003

Data ur SMS-registret diskuterades i två debattartiklar i läkartidningen våren 2003 av Jan Fagius respektive Jan Hillert. "Sjukdomsmodifierande behandling mot MS - framsteg med komplikationer" (jämte) Replik: "Problemet är under behandlingen!" av Jan Hillert (deb) 2003 nr 13 sid 1164-8.

En beskrivning av SMS-registret finns i den nya upplagan av "Multipel skleros - Metodpärm" som tryckts i en första upplaga på ett par hundra exemplar och som nu (2005) finns tillgänglig på Svenska MS-Sällskapetets hemsida.

Maria Turesson, med. kand., uppsats "Evidens-baserad Interferon-behandling i teori och praktik". Redovisades den 2/6 2003 (SMS-registret var delvis använt för att undersöka hur neurolog mottagning i Lund följer Läkemedelsverkets rekommendationer för interferon-behandling).

Gielen A, Khademi M, Muhallab S, Olsson T, Piehl F. Increased brain-derived neurotrophic factor expression in white blood cells of relapsing-remitting multiple sclerosis patients. *Scand J Immunol.* 2003 May;57(5):493-7.

Danilov AI, Andersson M, Bavand N, Wiklund NP, Olsson T, Brundin L. Nitric oxide metabolite determinations reveal continuous inflammation in multiple sclerosis. *J Neuroimmunol.* 2003 Mar; 136(1-2):112-8.